1	
2	
3	Evaluating the feasibility of study methods for a future trial-based economic
4	evaluation of a multistage shared decision-making program for type 2 diabetes
5	mellitus: protocol for a cluster-randomized controlled pilot study
6	
7	
8	
9	A. Tichler ^{1*} , D.F.L. Hertroijs ¹ , G.A.P.G. van Mastrigt ¹ , M.C.G.J. Brouwers ^{2,3} , D. Ruwaard ¹ , A.M.J.
10	Elissen ¹
11	
12	¹ Department of Health Services Research, Care and Public Health Research Institute (CAPHRI),
13	Faculty of Health, Medicine and Life Sciences (FHML), Maastricht University, Maastricht, the
14	Netherlands
15	
16	² Care and Public Health Research Institute (CAPHRI), Faculty of Health, Medicine and Life Sciences
17	(FHML), Maastricht University, Maastricht, the Netherlands
18	
19	³ Department of Internal Medicine, Division of Endocrinology and Metabolic Disease, Maastricht
20	University Medical Center+, Maastricht, the Netherlands
21	
22	
23	
24	*Corresponding author:
25	E-mail: a.tichler@maastrichtuniversity.nl (AT)
26	
27	NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

28 Abstract

29 Introduction

We developed a multistage shared decision-making program for type 2 diabetes that aims to support person-centered type 2 diabetes management in primary care. The program consists of an online patient decision aid, a preparatory consult for patients, and interprofessional training for healthcare professionals. The short- and long-term effectiveness of the multistage shared decision-making program needs to be researched in a trial-based economic evaluation. To evaluate the feasibility of study methods for future economic evaluation, we will conduct a pilot study that focuses on sample recruitment and retention, study management, and feasibility of outcome and cost measurements.

37

38 Methods and analysis

39 The multistage shared decision-making program will be pilot-tested in a cluster-randomized 40 controlled trial in four primary care practices (located in the region of Gorinchem, the Netherlands) 41 using a mixed-methods approach. The intervention practices will adopt the program, whereas the control 42 practices provide usual care. Data collection will include recruitment, retention, and consent rates, 43 patients' sociodemographic and clinical characteristics, and the assessment of primary and secondary 44 outcomes of the future trial-based economic evaluation. We will also collect data on the usage behavior 45 of patients when completing questionnaires of the primary and secondary outcomes (i.e. time needed to 46 complete questionnaires). Semi-structured interviews with patients will be conducted to obtain insights into the understandability and usability of measurement tools. Moreover, focus groups with healthcare 47 professionals from participating practices will be organized to complement the quantitative data on 48 sample representativeness and to assess the study management challenges of participating practices. 49

51 **Discussion**

The pilot will address uncertainties around the feasibility of a future trial-based economic evaluation, focusing on sample recruitment and retention, study management, and the feasibility of outcome and cost measurements. The results will guide the improvement of study procedures for the economic evaluation of our multistage shared decision-making program for type 2 diabetes.

57 Introduction

Type 2 diabetes mellitus (T2DM) is associated with significant levels of morbidity and 58 mortality, reduced quality of life, and increased healthcare costs [1]. National and international clinical 59 60 guidelines for T2DM emphasize the need for person-centered care, including shared decision-making (SDM), to decide on the best treatment course for an individual patient [2-4]. SDM is complex in T2DM 61 care due to the availability of many pharmacological and lifestyle treatment options. Patients and 62 63 healthcare professionals (HCPs) face difficult trade-offs in aligning treatment attributes (e.g. efficacy, side effects) with patients' clinical factors and preferences. SDM support is needed to reap the full 64 65 benefits of person-centered T2DM care. We developed a multistage SDM program for T2DM that 66 combines (1) an online patient decision aid (PDA) with (2) a preparatory consult for patients, and (3) interprofessional training in the PDA and SDM for HCPs [5]. The program was co-created with patients 67 with T2DM, healthcare professionals involved in T2DM care, and patient organizations. 68

69 Evidence shows that PDAs, in general, can reduce patients' decisional conflict, make them better informed, more involved and satisfied with their treatment choices, and have a positive effect on 70 71 the communication between patients and HCPs [6]. There is some evidence suggesting that PDAs, through their effective support of SDM, can lead to improvements in treatment adherence and 72 73 persistence, thereby resulting in better health outcomes and cost reduction [6]. However, the available evidence for these effects remains limited [6]. Our multistage SDM program for T2DM is a complex 74 intervention as defined by the Medical Research Council (MRC) [7]. It consists of multiple, interacting 75 76 components, targets a diverse group of end-users, and influences a range of short- and long-term 77 outcome measures. A trial-based economic evaluation with the multistage SDM program needs to be conducted to estimate short- and long-term effectiveness. It will strengthen the limited evidence about 78 79 the impact of person-centered care and SDM on mid and long-term outcomes such as treatment adherence, health outcomes, and costs. 80

Previous randomized controlled trials researching the effects of SDM support through PDAs for T2DM experienced several challenges related to study procedures (e.g. recruitment), resources (e.g. time necessary to complete questionnaires), and study management (e.g. personnel and data

management for participating practices) [8-12]. These challenges include, for example, difficulties in 84 recruiting patients, understandability of questionnaires, timely recruitment, and inadvertent recruitment 85 86 bias. Recognizing the challenges faced in previous research, small-scale piloting is crucial to address uncertainties around the feasibility of study methods and to improve the study procedures of an 87 economic evaluation [12, 13]. This article outlines the protocol for a cluster-randomized controlled pilot 88 89 study aimed at evaluating the feasibility of a future trial-based economic evaluation of a multistage SDM 90 program, including a PDA for T2DM in the Netherlands, compared to usual care [5]. The pilot study 91 specifically focuses on sample recruitment and retention, study management, and feasibility of outcome 92 and cost measurements. A mixed-methods approach will be used to identify and address potential challenges for future trial-based economic evaluation. 93

94

95 **Research questions**

The pilot aims to address uncertainties around the feasibility of study methods. This includes the 96 97 need for strategies to deal with recruitment and retention challenges to ensure a study sample that represents the diverse group of patients with T2DM for the intended economic evaluation [14]. 98 Moreover, acknowledging the high workload and time constraints experienced by HCPs, we aim to gain 99 insights into how to minimize additional burdens on participating practices [15, 16]. Finally, considering 100 101 the complexity of the measurement process and the understandability of the measurement tools, the 102 outcomes and costs will be measured in the pilot study to refine study procedures for the intended economic evaluation. Therefore, the research questions of this pilot study are: 103

- What strategies can be employed to effectively recruit and retain a demographically and
 clinically diverse sample of patients with T2DM?
- 106 2. How can we support primary care practices in effectively managing the challenges associated107 with study participation?
- 108 3. How can we feasibly measure relevant SDM outcomes, treatment adherence, health outcomes,
 109 and costs from a societal perspective for T2DM using valid and reliable measurement
 110 instruments?

Methods and analysis

This protocol follows a combination of the Consolidated Standards of Reporting Trials 112 (CONSORT) extension to pilot trials [17] and the Standard Protocol Items: Recommendations for 113 114 Interventional Trials (SPIRIT) checklist for reporting protocol studies [18, 19], as described by Thabane et al. [20] (S1-S2 File). For conducting and reporting the future economic evaluation, the Dutch 115 guidelines for economic evaluation [21] and the Consolidated Health Economic Evaluation Reporting 116 117 Standards 2022 (CHEERS 2022) Statement [22] will be followed, respectively. The pilot study starts 118 February 2024 and will last 15 months: 9 months for implementation (i.e. patient recruitment and data 119 collection) of the multistage SDM program, and 6 months for data analysis and reporting.

120

121 Setting

The majority of patients with T2DM in the Netherlands (90% in 2022) are treated in a primary care 122 setting organized by care groups [23]. Care groups are collaborations between healthcare professionals 123 (general practitioners and affiliated personnel) and are responsible for organizing, coordinating, and 124 125 providing care for patients with T2DM in their region [24]. A team comprising a general practitioner and practice/diabetes nurse provides treatment following the national guidelines for T2DM of the NHG 126 [25]. Since most Dutch patients with T2DM are treated in primary care, the multistage SDM program 127 was developed based on the NHG guideline for T2DM and will be pilot-tested in a general practice 128 129 setting. Therefore, we collaborate with the primary care group 'Huisarts & Zorg', a group of 75 general 130 practices located in the region of Gorinchem (a municipality in South Holland) to recruit practices and 131 patients. Four primary care practices from the care group 'Huisarts & Zorg' will be included in this pilot 132 study.

133

134 Study design

135 The multistage SDM program will be piloted in a cluster-randomized controlled trial using a 136 mixed-methods approach to answer questions related to sample recruitment and retention, study

management, and feasibility of outcome and cost measurements. Randomization will be conducted by 137 cluster (i.e. primary care practices) to avoid possible contamination between the intervention and control 138 group [26]. Two primary care practices will be randomly assigned to the intervention group and two to 139 the control group. Simple randomization will be used to assign each primary care practice to a group 140 with an equal probability (1:1 allocation) using a computerized random number generator [27]. Both 141 patients with T2DM and HCPs are not blinded to the group assigned to them. Patients and HCPs from 142 143 the intervention practices will have access to the multistage SDM program. They will receive an account 144 to gain access to the PatientPlus platform, where the PDA is available. Patients and HCPs from the 145 control practices will provide and receive usual care according to the national guidelines for T2DM of the Dutch College of General Practitioners (NHG) [25]. They will not have access to the multistage 146 program. Data will be collected from patients and healthcare professionals in both the intervention and 147 control practices. 148

149

150 **Participants**

To be able to recruit a diverse population of patients with T2DM, we aim to include general 151 practices from the care group 'Huisarts & Zorg' that differ in terms of the sociodemographic background 152 of their patient panels. HCPs from the participating practices will be asked to recruit patients who: 1) 153 are eighteen years or older; 2) need to decide on T2DM treatment based on the NHG guideline 154 155 (medication and/or lifestyle); and 3) speak Dutch at a necessary level to complete questionnaires and ensure involvement in SDM. We will only exclude patients who have severe cognitive impairments that 156 hamper SDM. Patients will be enrolled in the study after receiving face-to-face and written information 157 158 about the research from their HCP and after giving written informed consent.

159

160 Intervention

161 The multistage SDM program combines an online PDA with a preparatory consultation for 162 patients as well as an interprofessional training in the PDA and SDM for HCPs (Fig 1). The program

was co-created with a multidisciplinary steering group representing all relevant stakeholders in Dutchdiabetes care. The development of the PDA for T2DM is described in detail elsewhere [5].

165

166 Fig 1. Overview of the multistage shared decision-making program for type 2 diabetes mellitus.

167 SDM: shared decision-making; PDA: patient decision aid; T2DM: Type 2 Diabetes Mellitus.

168

The PDA is available in the online catalog of PatientPlus (https://www.keuzehulp.info/frontpage/keuzehulpen/diabetes-type-2, Dutch only), the largest supplier of PDAs in the Netherlands. In line with the International Patient Decision Aids Standards (IPDAS) guidance, the PDA comprises five sections: 1) information about T2DM and the available treatment options; 2) a comparison of treatment options based on, for example, the risk of cardiovascular disease and effect on daily life; 3) questions to assess patients' knowledge; 4) value-clarification exercise; and 5) summary of the patient's journey [28, 29].

To prepare and empower patients for SDM, our multistage program comprises a one-to-one preparatory consultation with a trained facilitator. Each practice can decide whether a practice nurse, medical assistant or other HCP will serve as a trained facilitator. The consultation will last 20-30 minutes and is intended to help patients effectively use the PDA and provide them with the knowledge and confidence needed to fully participate in SDM. The preparatory consultation takes place before the clinical encounter where the treatment decision is made by a patient and HCP (i.e. a GP or specialized nurse who can prescribe medication).

All participating HCPs (including the trained facilitators) from included intervention practices receive a 2-hour interactive interprofessional training in SDM and the PDA, including communication techniques and general instructions to increase SDM knowledge. HCPs will receive accreditation for their participation in the training. The training is offered by PatientPlus. One intervision meeting between the trained facilitators from all participating practices will be held to stimulate interprofessional training.

190 Sample size calculation

The pilot study is a preparation for a large trial-based economic evaluation and therefore setting 191 the sample size for the pilot study in order to minimize the total sample size of the pilot study and main 192 193 trial together is the most suitable method of sample size calculation [30]. The sample size calculation 194 for the pilot study is based on a 90% powered main trial and an estimated medium (between 0.3 and 0.7) effect size in the decisional conflict score (primary outcome of the intended economic evaluation) [31]. 195 Using the stepped rules of thumb, the sample size for the pilot study would be 30 patients with T2DM 196 [30]. Due to possible loss to follow-up and drop-out, the sample size will be increased by a third. So, 197 the sample size for this pilot study will be set at 40 patients with T2DM, with 20 patients assigned to 198 199 each arm.

200

201 **Outcome measures**

The pilot study will focus on three aspects: 1) sample recruitment and retention; 2) study management; and 3) feasibility of outcome and cost measurements. Each aspect has its own relevant outcome measures and measurement instruments.

205

206 Research question 1. Sample recruitment and retention

To assess the extent to which a representative sample of T2DM patients is included and retained, quantitative data will be collected on: (1) recruitment, retention and consent rates; (2) time required to recruit the target sample size; and (3) sociodemographic and clinical characteristics. To interpret the quantitative data and learn how to improve sample representativeness for the intended trial-based economic evaluation, additional qualitative data will be collected through one-hour focus groups with HCPs from the participating practices.

214 Research question 2. Study management

The focus groups with HCPs from participating practices will also be used to assess practices' study management challenges. An interview guide, consisting of a set of semi-structured questions related to study management (e.g. did the practice have the time to perform the tasks they committed to doing? Did they experience any capacity issues?) will be used to guide the focus group.

219

220 Research question 3. Feasibility of outcome and cost measurements

221 We will assess the feasibility of primary and secondary outcome measurements of the intended trial-based economic evaluation. The primary and secondary outcomes will solely be measured to assess 222 its measurement feasibility and not to determine the (cost-)effectiveness and cost-utility of the 223 multistage SDM program. The primary outcomes will focus on short-term SDM outcomes. Primary 224 225 outcomes include patient decisional conflict (using the 16-item Decisional Conflict Scale, DCS [32]), level of SDM as perceived by patients (based on the 3-item CollaboRATE survey [33, 34] and SDM-226 Q-9 questionnaire [35]), level of SDM as perceived by HCPs (using the SDM-Q-Doc questionnaire 227 [35]), and patient knowledge (with 9 tailor-made questions assessing patient's understanding of the 228 229 glucose-lowering treatments). The DCS, CollaboRATE, SDM-Q-9, and SDM-Q-Doc questionnaires will be used for this pilot study due to their validity and wide applicability in assessing SDM in 230 231 healthcare. The long-term cost-effectiveness and cost-utility of our multistage SDM program will serve 232 as secondary outcomes in the intended trial-based economic evaluation. Assessing societal costs and 233 health-related quality of life is essential for conducting a cost-utility analysis since it allows us to 234 compare the multistage program with usual care by estimating how much it costs to reach improvements in individuals' quality of life [36]. Moreover, in the future trial-based economic evaluation, we will also 235 236 conduct a cost-effectiveness analysis to estimate how much it costs to reach improvements in relevant 237 health outcomes (i.e. glycemic control). Therefore, secondary outcomes include glycemic control (HbA1c obtained via the HCP), societal costs (measured with an adapted version of the iMTA 238 Productivity Costs Questionnaire (iPCQ) and iMTA Medical Consumption Questionnaire (iMCQ) [37, 239 38]), health-related quality of life (measured with the Dutch EuroQol (EQ) 5D-5L questionnaire 240

assessing quality of life [39]), and medication adherence (measured with the Medication AdherenceReport Scale [40] and prescription data obtained via the pharmacist).

243 Table 1 provides an overview of the primary and secondary outcomes of the future trial-based economic evaluation, including their measurement tools. Semi-structured interviews with patients will 244 be held to gain insight into the understandability and accessibility of the measurement tools. Interviews 245 246 will be conducted either in person or online via Microsoft Teams, depending on the preference of the 247 patient. Moreover, we will collect data on the usage behavior of patients when completing the 248 questionnaires (i.e. time needed to complete questionnaires) and the amount of missing data. The focus groups with HCPs from participating practices will also be used to evaluate the understandability of the 249 250 SDM-Q-Doc questionnaire.

251

Table 1. Outcomes of the intended large-scale trial-based economic evaluation, including their measurement tools.

Outcome	Measurement tool	Components
Patients		
Decisional	Decisional Conflict	Patients will be asked to reflect on the treatment
Conflict	Scale (DCS) [32]	decision they made with their HCP and respond to 16
		statements in the DCS using a five-point Likert scale
		(from completely agree to completely disagree).
Level of SDM	CollaboRATE	3 statements that assess patients' perception of being
	survey [33, 34]	informed and engaged in decision-making steps on a
		scale of zero (no effort was made) to nine (every effort
		was made)
	SDM-Q-9	The questionnaire contains nine statements each
	questionnaire [35]	describing a different step of the SDM process. All
		items are scored on a six-point Likert scale from zero

(completely disagree) to five (completely agree). The
questionnaire also includes two open-ended questions on
what health problem was the subject of the consultation
and which decision was made.

Patient knowledge	9 tailor-made	Assessing patients' understanding of the (risks and			
	multiple-choice	benefits of) glucose-lowering treatments.			
	questions				
Medication	Medication	Assessing intentional and unintentional non-adherence			
adherence	Adherence Report	(self-reported). Patients are asked to rate the frequency			
	Scale (MARS) [40]	of events (i.e. forgetting a dose, changing a dose) on a			
		five-point Likert Scale (ranging from never to always).			
	Prescription data	Patients' pharmacy records for all T2DM medication			
		will be collected.			
Glycemic control	Primary care data	Glycemic control is assessed by obtaining HbA1c data			
		from the primary care practice.			
Costs (resource	An adapted version	The adapted version of the iMTA Productivity Costs			
use)	of the iMCQ and	Questionnaire (iPCQ) and the iMTA Medical			
	iPCQ questionnaire	Consumption Questionnaire (iMCQ) aims to measure			
	[37, 38]	relevant (non-)healthcare use as well as costs important			
		to patients and families.			
Health-related	Dutch EuroQol	The EQ 5D-5L assesses quality of life and includes the			
quality of life	(EQ) 5D-5L	EQ-5D dimension and the EQ visual analog scale			
	(quality of life)	(VAS). EQ-5D comprises five dimensions: mobility,			
	[39]	self-care, usual activities, pain, and anxiety. Each			
		dimension of the EQ-5D is scored on a five-point Likert			
		score (from no problems to extreme problems). The EQ			

VAS is used to assess the patient's self-reported health

on a visual analog scale.

Healthcare professionals				
Level of SDM	SDM-Q-Doc	SDM-Q-9 questionnaire adapted to the HCP viewpoint		
	questionnaire [35]	to assess the extent of SDM during a consultation from		
		the HCP perspective.		

254 HCP: healthcare professional; SDM: shared decision-making.

255 Data collection and timeline

256 Patients from the intervention practices are requested to complete the questionnaires via the 257 online PatientPlus platform and patients from the control practices will complete questionnaires via 258 Qualtrics [41]. They will receive automatic notifications (via mail) prompting them to complete the follow-up questionnaires at 3 and 9 months follow-up. Additionally, automated reminders will be sent 259 260 if the patient has not yet completed the questionnaire. HCPs from the control and intervention practices 261 will complete the questionnaire via Qualtrics [41]. The schedule of study enrolment and assessment can 262 be found in Table 2. Baseline measurements will capture sociodemographic and clinical patient characteristics, patient knowledge, medication adherence, costs, and health-related quality of life. In 263 both study arms, patients complete the DCS, CollaboRATE survey, and SDM-Q-9 questionnaire directly 264 265 following the clinical encounter where a treatment decision is made. At the same time, HCPs complete the SDM-Q-Doc questionnaire. Follow-ups at 3 months and 9 months will facilitate the measurement 266 of medication adherence, costs, and health-related quality of life. Semi-structured interviews with 267 patients will be held within 1 month after study participation and the focus groups with HCPs from 268 participating practices will be held at the end of the 9 months of implementation. Upon completion of 269 270 data collection at 9-month follow-up, we will gather information on the glycemic control (at baseline, and 3- and 9-month follow-up) of participating patients by obtaining their HbA1c values through their 271 272 primary care practice.

274 Table 2. Schedule of study enrolment and assessment.

		Enrolment				
Time point			t0	t1	t2	t
Enrolment	Eligibility	Х				
	Informed consent	Х				
Assessment	Sociodemographic and clinical characteristics		X			
	Decisional Conflict			х	X	
	Patient-rated level of SDM			х	X	
	HCP-level of SDM			х	X	
	Patient knowledge		X			
	Medication adherence		x		x	
	Glycemic control		x		x	
	Costs (resource use)		X		X	
	Health-related quality of life		x		x	
	Semi-structured interviews with patients			x		
	Focus group with HCPs					

t0 = baseline measurement; t1 = directly following the clinical encounter where a treatment decision is
made; t2 = 3-month follow-up; t3 = 9-month follow-up. SDM: shared decision-making, HCP: healthcare
professional.

278

279 Data analysis

Descriptive analysis, i.e. counts and percentages for non-continuous data and mean scores and standard deviations for continuous data, will be reported for all variables. This includes sociodemographic and clinical characteristics, outcomes of the future economic evaluation, and estimates related to feasibility (e.g. recruitment rates and time to complete questionnaires). Moreover, we will analyze the missing data by identifying the amount of missing data and complementing this information with the results of the qualitative analysis. Descriptive analysis will be performed in Rstudio

[42]. Due to the nature of the pilot study, no statistical tests on the primary and secondary outcomes willbe conducted.

288 Interviews and focus groups will be audio-recorded and transcribed ad verbatim, and analyzed in ATLAS.ti using thematic analysis with an inductive approach following three steps [43, 44]. First, 289 the transcripts will be read and re-read in a process called 'familiarization'. Second, phrases, sentences, 290 291 and paragraphs with meaningful topics will be isolated and labeled by a code for each interview 292 transcript (independently by two researchers). Third, themes are developed by clustering codes with 293 similar meanings or interrelations, to understand, interpret, and report the main insights flowing from 294 the data. Analysis of the interviews and focus groups will be used to improve the questionnaires (e.g. formulation of questions and possible adaptation to the cost questionnaire), recruitment strategies, and 295 study procedures. 296

The data management process (i.e. data collection, data processing, data quality, and data analysis) and possible improvements thereof will be discussed with the research team in three 2-hour meetings throughout the study period.

300

301 Ethical considerations and declarations

The Medical Ethics Review Committee of the academic hospital of Maastricht (azM) and 302 303 Maastricht University confirmed that the Medical Research Involving Human Subjects Act does not 304 apply to the pilot study and that official approval is not required (METC2023-0114). Patients will be enrolled in the study after receiving face-to-face and written information about the research and after 305 giving written informed consent. Participants' data will be used and retained by the researchers of 306 307 Maastricht University in compliance with the EU General Data Protection Regulation. Some of the data will be collected via PatientPlus. PatientPlus has an information security management system that is 308 ISO27001 and NEN7510 certified. Researchers will be provided with an account for PatientPlus to 309 access the research data of patients. PatientPlus has only access to the anonymized data. The collected 310 311 data will be stored on the secure server of Maastricht University. All participants in this study will be 312 given an ID number to ensure the confidentiality of the patients and HCPs. Data in reports and

publications of this pilot study will not be traceable to the research participants. Research participants
have the right to withdraw from the research and withdraw their consent to the use of personal data at
any time during the study.

316

317 **Discussion**

318 This protocol outlines the approach for pilot testing our multistage SDM program in primary 319 care. Our primary objective is to address uncertainties around the feasibility of study methods, focusing on aspects such as sample recruitment and retention, study management, and the feasibility of outcome 320 321 and cost measurements. Given that T2DM affects a large and diverse group of patients, it is important 322 to ensure that the study participants accurately represent this diversity, as it is essential for our intended 323 trial-based economic evaluation [14]. Previous randomized controlled trials researching the effects of PDAs for T2DM experienced recruitment challenges [8-11]. These trials reported difficulties in 324 325 recruiting sufficient participants, timely recruitment, and inadvertent recruitment bias. Moreover, some 326 trials were unable to include a representative sample of patients with T2DM [9, 11]. It is also important 327 to acknowledge that the PDA has a digital format and questionnaires need to be completed digitally. 328 This may pose a limitation for individuals with low digital literacy, especially among older adults [45-329 47]. We will therefore place a strong emphasis on the feasibility of the study processes in terms of 330 recruitment, retention, and consent rates within the pilot study. This will improve our understanding of 331 strategies to include a representative and diverse group of participants and we can apply these insights to the recruitment process of the intended trial-based economic evaluation. 332

HCPs in primary care practices are faced with a high workload, time constraints, and stress which are also identified as barriers to research participation [15, 16, 48]. To avoid willingness and capacity problems of the participating practices related to the study, it is important to limit time expenses and paperwork, and to provide adequate information and support. Therefore, as part of the pilot study, we focus on how we can support general practices in effectively managing the challenges associated with study participation. These insights will be instrumental in ensuring the successful implementation of the multistage program into routine practice while minimizing the additional burden on practices.

340 There are valid and reliable instruments available (except for the cost questionnaire) for the primary and secondary outcomes of the intended trial-based economic evaluation [32-35, 39, 40]. The 341 342 measurement process can be complex since outcomes are collected using different methods, from 343 different sources, and at various time points. It is important to avoid data management problems and ensure successful data triangulation in the large-scale study. Hence, the primary and secondary outcomes 344 will be measured and analyzed during the small-scale pilot study. In the pilot study, we also focus on 345 346 the understandability and accessibility of the measurement tools and possible improvements thereof. 347 This is especially important since approximately 24.5% of the Dutch population experience low health 348 literacy and may therefore face difficulties when completing questionnaires [49]. Overall, the insights gained from the pilot study will guide the refinement of the study procedures and intervention 349 350 components for the intended trial-based economic evaluation.

351 Our pilot study will contribute to the existing knowledge of effectively implementing PDAs into clinical practice. Previous research showed that only 44% of existing PDAs for different conditions are 352 effectively integrated into clinical practice following their trial [46]. The intended trial-based economic 353 354 evaluation strengthens the limited evidence about the impact of person-centered care and SDM on mid 355 and long-term outcomes such as treatment adherence, health outcomes, and societal costs. It will contribute to gaining a more comprehensive understanding of the potential benefits and challenges of 356 357 integrating person-centered SDM interventions into practice. Addressing these knowledge gaps is 358 essential to convince HCPs, policymakers, and payers to invest in the widespread implementation of 359 effective SDM support for person-centered care.

360

361 **Dissemination plan**

The results of this pilot study will be disseminated by means of conference presentations and international peer-reviewed scientific journals. Moreover, attention will be given to promoting the multistage SDM program among patients with T2DM and healthcare professionals within primary care. This will help the future recruitment of patients with T2DM and primary care practices for the intended trial-based economic evaluation. Our collaboration with the steering group consisting of patients with

T2DM, healthcare professionals, and patient organizations, established at the beginning of the development of the multistage SDM program, will be continued for this pilot study. The steering group and our collaboration with care group 'Huisarts & Zorg' and PatientPlus add valuable expertise and experience from practice and policy as future end-users of our multistage SDM program. This collaboration will help improve the implementation and dissemination of the program.

373 **References**

- International Diabetes Federation. IDF Diabetes Atlas. Brussels, Belgium: 2021. Available at:
 https://www.diabetesatlas.org.
- American Diabetes Association Professional Practice C. 9. Pharmacologic Approaches to
 Glycemic Treatment: Standards of Care in Diabetes—2024. Diabetes Care.
 2023;47(Supplement 1):S158-S78. doi: 10.2337/dc24-S009.
- Davies MJ, Aroda VR, Collins BS, Gabbay RA, Green J, Maruthur NM, et al. Management of
 Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes
 Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes
 Care. 2022;45(11):2753-86. doi: 10.2337/dci22-0034.
- 383 4. Nederlands Huisartsen Genootschap. NHG-standaard Diabetes mellitus type 2 (versie 5.6).
 384 2023.
- 385 5. Tichler A, Hertroijs D, Ruwaard D, Brouwers M, Elissen A. Development of a patient decision aid for type 2 diabetes mellitus: a patient-centered approach. Research Square [Preprint] [posted 386 cited 2023 Oct 11]. 2023. Epub 10 October 387 2023 Oct 10; 2023. doi: 388 https://doi.org/10.21203/rs.3.rs-3395717/v1.
- Stacey D, Legare F, Col NF, Bennett CL, Barry MJ, Eden KB, et al. Decision aids for people
 facing health treatment or screening decisions. Cochrane Database Syst Rev.
 2014;(1):CD001431. Epub 2014/01/28. doi: 10.1002/14651858.CD001431.pub4. PubMed
 PMID: 24470076.
- 393 7. Skivington K, Matthews L, Simpson SA, Craig P, Baird J, Blazeby JM, et al. A new framework
 394 for developing and evaluating complex interventions: update of Medical Research Council
 395 guidance. BMJ. 2021;374:n2061. doi: 10.1136/bmj.n2061.
- Branda ME, LeBlanc A, Shah ND, Tiedje K, Ruud K, Van Houten H, et al. Shared decision
 making for patients with type 2 diabetes: a randomized trial in primary care. BMC Health Serv
 Res. 2013;13:301-. doi: 10.1186/1472-6963-13-301. PubMed PMID: 23927490.

- 399 9. Kellar I, Mann E, Kinmonth AL, Prevost AT, Sutton S, Marteau TM. Can informed choice
 400 invitations lead to inequities in intentions to make lifestyle changes among participants in a
 401 primary care diabetes screening programme? Evidence from a randomized trial. Public Health.
 402 2011;125(9):645-52. doi: https://doi.org/10.1016/j.puhe.2011.05.010.
- Mathers N, Ng CJ, Campbell MJ, Colwell B, Brown I, Bradley A. Clinical effectiveness of a
 patient decision aid to improve decision quality and glycaemic control in people with diabetes
- 405 making treatment choices: a cluster randomised controlled trial (PANDAs) in general practice.
 406 BMJ Open. 2012;2(6):e001469. doi: 10.1136/bmjopen-2012-001469.
- 407 11. Mullan RJ, Montori VM, Shah ND, Christianson TJH, Bryant SC, Guyatt GH, et al. The
 408 Diabetes Mellitus Medication Choice Decision Aid: A Randomized Trial. Arch Intern Med.
 409 2009;169(17):1560-8. doi: 10.1001/archinternmed.2009.293.
- Thabane L, Ma J, Chu R, Cheng J, Ismaila A, Rios LP, et al. A tutorial on pilot studies: the
 what, why and how. BMC Med Res Methodol. 2010;10(1):1. doi: 10.1186/1471-2288-10-1.
- 412 13. Van Teijlingen E, Hundley V. The importance of pilot studies. Social research update.
 413 2001;(35):1-4.
- Health. 2002;92(4):543-8. doi: 10.2105/ajph.92.4.543. PubMed PMID: 11919048; PubMed
 Central PMCID: PMCPMC1447113.
- McKinley N, McCain RS, Convie L, Clarke M, Dempster M, Campbell WJ, Kirk SJ. Resilience,
 burnout and coping mechanisms in UK doctors: a cross-sectional study. BMJ Open.
 2020;10(1):e031765. Epub 20200127. doi: 10.1136/bmjopen-2019-031765. PubMed PMID:
 31988223; PubMed Central PMCID: PMCPMC7045750.
- 421 16. West CP, Dyrbye LN, Shanafelt TD. Physician burnout: contributors, consequences and
 422 solutions. J Intern Med. 2018;283(6):516-29. Epub 20180324. doi: 10.1111/joim.12752.
 423 PubMed PMID: 29505159.
- Eldridge SM, Chan CL, Campbell MJ, Bond CM, Hopewell S, Thabane L, et al. CONSORT
 2010 statement: extension to randomised pilot and feasibility trials. Pilot and Feasibility Studies.
 2016;2(1):64. doi: 10.1186/s40814-016-0105-8.

- 427 18. Chan A-W, Tetzlaff JM, Altman DG, Laupacis A, Gøtzsche PC, Krleža-Jerić K, et al. SPIRIT
- 428 2013 Statement: Defining Standard Protocol Items for Clinical Trials. Ann Intern Med.
 429 2013:158(3):200-7. doi: 10.7326/0003-4819-158-3-201302050-00583.
- 430 19. Chan A-W, Tetzlaff JM, Gøtzsche PC, Altman DG, Mann H, Berlin JA, et al. SPIRIT 2013
- 431 explanation and elaboration: guidance for protocols of clinical trials. BMJ : British Medical
- 432 Journal. 2013;346:e7586. doi: 10.1136/bmj.e7586.
- Thabane L, Lancaster G. A guide to the reporting of protocols of pilot and feasibility trials. Pilot
 and Feasibility Studies. 2019;5(1):37. doi: 10.1186/s40814-019-0423-8.
- 435 21. Nederland Z. Richtlijn voor het uitvoeren van economische evaluaties in de gezondheidszorg
 436 (versie 2024). 2024. p. 38.
- Husereau D, Drummond M, Augustovski F, de Bekker-Grob E, Briggs AH, Carswell C, et al.
 Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022)
 Statement: Updated Reporting Guidance for Health Economic Evaluations. Value Health.
 2022;25(1):3-9. doi: https://doi.org/10.1016/j.jval.2021.11.1351.
- 441 23. InEen. Benchmark Transparante Ketenzorg 2022. Rapportage zorgprogramma's diabetes
 442 mellitus type 2, COPD, Astma en Vasculair Risico Management bij patiënten met een
 443 hartvaatziekte en een verhoogd risico op hartvaatziekten 2023.
- 444 24. Struijs JN, van Til JT, Baan CA. Experimenteren met de keten-dbc diabetes. Bilthoven: RIVM,
 445 2009.
- 446 25. Nederlands Huisartsen Genootschap (NHG). Behandeling bij diabetes type 2 2022. Available
 447 from: https://www.thuisarts.nl/diabetes-type-2/ik-heb-diabetes-type-2#behandeling-bij448 diabetes-type-2.
- 449 26. Fayers PM, Jordhùy MS, Kaasa S. Cluster-randomized trials. Palliat Med. 2002;16(1):69-70.
 450 doi: 10.1191/0269216302pm503xx.
- 451 27. Kang M, Ragan BG, Park JH. Issues in outcomes research: an overview of randomization
 452 techniques for clinical trials. J Athl Train. 2008;43(2):215-21. Epub 2008/03/18. doi:
 453 10.4085/1062-6050-43.2.215. PubMed PMID: 18345348; PubMed Central PMCID:
 454 PMCPMC2267325.

- Elwyn G, O'Connor A, Stacey D, Volk R, Edwards A, Coulter A, et al. Developing a quality
 criteria framework for patient decision aids: online international Delphi consensus process. BMJ
 (Clinical research ed). 2006;333(7565):417-. Epub 2006/08/14. doi:
 10.1136/bmj.38926.629329.AE. PubMed PMID: 16908462.
- Elwyn G, O'Connor AM, Bennett C, Newcombe RG, Politi M, Durand MA, et al. Assessing the 459 29. quality of decision support technologies using the International Patient Decision Aid Standards 460 461 instrument (IPDASi). PLoS One. 2009;4(3):e4705. Epub 2009/03/05. doi: 462 10.1371/journal.pone.0004705. PubMed PMID: 19259269; PubMed Central PMCID: PMCPMC2649534. 463
- Whitehead AL, Julious SA, Cooper CL, Campbell MJ. Estimating the sample size for a pilot
 randomised trial to minimise the overall trial sample size for the external pilot and main trial for
 a continuous outcome variable. Stat Methods Med Res. 2016;25(3):1057-73. Epub 2015/06/21.
 doi: 10.1177/0962280215588241. PubMed PMID: 26092476; PubMed Central PMCID:
 PMCPMC4876429.
- 469 31. Yu CH, Ivers NM, Stacey D, Rezmovitz J, Telner D, Thorpe K, et al. Impact of an
 470 interprofessional shared decision-making and goal-setting decision aid for patients with diabetes
 471 on decisional conflict study protocol for a randomized controlled trial. Trials. 2015;16(1):286.
 472 doi: 10.1186/s13063-015-0797-8.
- 473 32. O'Connor AM. Validation of a Decisional Conflict Scale. Med Decis Making. 1995;15(1):25474 30. doi: 10.1177/0272989X9501500105.
- 33. Barr PJ, Thompson R, Walsh T, Grande SW, Ozanne EM, Elwyn G. The psychometric
 properties of CollaboRATE: a fast and frugal patient-reported measure of the shared decisionmaking process. J Med Internet Res. 2014;16(1):e2-e. doi: 10.2196/jmir.3085. PubMed PMID:
 24389354.
- 479 34. Elwyn G, Barr PJ, Grande SW, Thompson R, Walsh T, Ozanne EM. Developing CollaboRATE:
 480 a fast and frugal patient-reported measure of shared decision making in clinical encounters.
 481 Patient Educ Couns. 2013;93(1):102-7. Epub 2013/06/19. doi: 10.1016/j.pec.2013.05.009.
 482 PubMed PMID: 23768763.

- 35. Rodenburg-Vandenbussche S, Pieterse AH, Kroonenberg PM, Scholl I, van der Weijden T,
 Luyten GP, et al. Dutch Translation and Psychometric Testing of the 9-Item Shared Decision
 Making Questionnaire (SDM-Q-9) and Shared Decision Making Questionnaire-Physician
 Version (SDM-Q-Doc) in Primary and Secondary Care. PLoS One. 2015;10(7):e0132158. Epub
- 487 2015/07/08. doi: 10.1371/journal.pone.0132158. PubMed PMID: 26151946; PubMed Central
- 488 PMCID: PMCPMC4494856.
- 489 36. Fox-Rushby J. CJ. Economic Evaluation. London: Oxford University Press; 2006.
- 490 37. <u>www.imta.nl</u> (iMTA Productivity and Health Research Group. Handleiding iMTA Medical Cost
 491 Questionnaire (*i*MCQ) Rotterdam: iMTA, Erasmus Universiteit Rotterdam, 2018)
- 492 38. <u>www.imta.nl</u> (iMTA Productivity and Health Research Group. Handleiding iMTA Productivity
 493 Cost Questionnaire (*i*PCQ). Rotterdam: iMTA, Erasmus Universiteit, 2018)
- 494 39. EuroQol. EuroQol 2017. Available from: <u>https://euroqol.org/eq-5d-instruments/eq-5d-3l-</u>
 495 about/.
- 496 40. Chan AHY, Horne R, Hankins M, Chisari C. The Medication Adherence Report Scale: A
 497 measurement tool for eliciting patients' reports of nonadherence. Br J Clin Pharmacol.
 498 2020;86(7):1281-8. Epub 20200518. doi: 10.1111/bcp.14193. PubMed PMID: 31823381;
 499 PubMed Central PMCID: PMCPMC7319010.
- 41. Qualtrics. Provo, Utah, USA, 2005. Available from: https://www.qualtrics.com/.
- 501 42. Team R. RStudio: Integrated Development for R. 1.4.1106 ed. Boston, MA: RStudio, PBC;
 502 2020.
- 503 43. ATLAS.ti Scientific Software Development GmbH. ATLAS.ti Scientific Software
 504 Development GmbH.
- 505 44. Braun V, Clarke V. Using thematic analysis in psychology. Qualitative Research in Psychology.
 506 2006;3(2):77-101. doi: 10.1191/1478088706qp063oa.
- Hargittai E, Piper AM, Morris MR. From internet access to internet skills: digital inequality
 among older adults. Universal Access in the Information Society. 2019;18(4):881-90. doi:
 10.1007/s10209-018-0617-5.

510	46.	Stacey D, Suwalska V, Boland L, Lewis KB, Presseau J, Thomson R. Are Patient Decision Aids
511		Used in Clinical Practice after Rigorous Evaluation? A Survey of Trial Authors. Med Decis
512		Making. 2019;39(7):805-15. Epub 2019/08/20. doi: 10.1177/0272989x19868193. PubMed
513		PMID: 31423911.

- 514 47. van Deursen AJ, van Dijk JA. The first-level digital divide shifts from inequalities in physical
- access to inequalities in material access. New Media Soc. 2019;21(2):354-75. Epub 2019/03/20.
- 516 doi: 10.1177/1461444818797082. PubMed PMID: 30886536; PubMed Central PMCID:
 517 PMCPMC6380454.
- 518 48. Brodaty H, Gibson LH, Waine ML, Shell AM, Lilian R, Pond CD. Research in general practice:
- a survey of incentives and disincentives for research participation. Ment Health Fam Med.
- 520 2013;10(3):163-73. PubMed PMID: 24427184; PubMed Central PMCID: PMCPMC3822664.
- 49. Willems AEM, Heijmans M, Brabers AEM, Rademakers J. Gezondheidsvaardigheden in
 Nederland: factsheet cijfers 2021. Utrecht: Nivel. 2022.

523 Supporting information

- 524 S1 File. SPIRIT checklist.
- 525 S2 File. CONSORT checklist.
- 526 S3. File. Protocol

